The results of the distribution of clinical manifestations of the three groups showed that the clinical manifestations present in MNOS patients were also reported in the MOG-AD group or the anti-NMDAR encephalitis group; there was a difference in the incidence of clinical manifestations between MNOS patients and MOG-AD/anti-NMDAR encephalitis patients (Figure 2). This evidence concerns the gene MOG and encephalitis.